PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series

por Tan, Sirui, Yu, Jing, Huang, Qiyue, Zhou, Nan, Gou, Hongfeng
Publicado 2022

Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy

por Yu, Jing, Zhang, Xi, Huang, Qiyue, Tan, Sirui, Xiong, Xianze, Gou, Hongfeng
Publicado 2021

Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review

por Tan, Sirui, Yu, Jing, Huang, Qiyue, Zhou, Nan, Xiong, Xianze, Gou, Hongfeng
Publicado 2022

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)

por Zhou, Nan, Li, Xiaofen, Yang, Yu, Tan, Sirui, Zhang, Shunyu, Huang, Qiyue, Gou, Hongfeng
Publicado 2023